Literature DB >> 3641695

C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.

Y C Ng, D K Peters.   

Abstract

Fluid phase C3 conversion by C3 nephritic factor (C3NeF) is usually easily detectable and forms the basis of the C3NeF screening test. We have described a group of patients with membranoproliferative glomerulonephritis or partial lipodystrophy and hypocomplementaemia who have an unusual C3NeF which stabilizes cell-bound C3 convertase of the alternative pathway (C3bBb) but causes such weak fluid phase C3 conversion that a C3NeF screening test is negative. These patients have low concentrations of C5 in serum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3641695      PMCID: PMC1542295     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Heterogeneity of nephritic factor and its identification as an immunoglobulin.

Authors:  A E Davis; J B Ziegler; E W Gelfand; F S Rosen; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

3.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

4.  Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.

Authors:  J G Sissons; J Liebowitch; N Amos; D K Peters
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

5.  A new function of the activated third component of complement: binding to C5, an essential step for C5 activation.

Authors:  W Vogt; G Schmidt; B Von Buttlar; L Dieminger
Journal:  Immunology       Date:  1978-01       Impact factor: 7.397

6.  Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor.

Authors:  M R Daha; K F Austen; D T Fearon
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

7.  Complement studies in membrano-proliferative glomerulonephritis.

Authors:  D K Peters; A Martin; A Weinstein; J S Cameron; T M Barratt; C S Ogg; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1972-07       Impact factor: 4.330

8.  The complement abnormalities of lipodystrophy.

Authors:  J G Sissons; R J West; J Fallows; D G Williams; B J Boucher; N Amos; D K Peters
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

9.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

Review 10.  Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.

Authors:  J S Cameron; D R Turner; J Heaton; D G Williams; C S Ogg; C Chantler; G B Haycock; J Hicks
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

View more
  4 in total

Review 1.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

2.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

3.  Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Authors:  Roberta Donadelli; Patrizia Pulieri; Rossella Piras; Paraskevas Iatropoulos; Elisabetta Valoti; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

4.  Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.

Authors:  Alyssa C Gilmore; Yuchun Zhang; H Terence Cook; Deborah P Lavin; Suresh Katti; Yi Wang; Krista K Johnson; SungKwon Kim; Matthew C Pickering
Journal:  Kidney Int       Date:  2020-10-28       Impact factor: 10.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.